GENEVA, Switzerland–(BUSINESS WIRE)–Selexis SA, a JSR Life Sciences Company, today announced key promotions across its scientific and operational leadership teams. Effective immediately, the following individuals have been promoted: Myriam Adam, PhD, to vice president, operations and intellectual property; Séverine Fagète, PhD, to vice president, cell line development services; and Valérie Le Fourn, PhD, to vice president, research.
“Amid this global health crisis caused by COVID-19, Selexis remained operational and maintained business continuity to serve our large portfolio of customers worldwide. By quickly implementing staggered laboratory shifts and upholding safe, efficient practices, we suffered no business disruptions. Given these unique circumstances, it is my pleasure to share the good news that Myriam, Séverine and Valérie have earned well-deserved promotions,” said Igor Fisch, PhD, CEO, Selexis SA. “Not only have they exceeded expectations in their respective roles within the company but they have also proven themselves as strong leaders in an industry that sometimes overlooks the success and advancement of women. As CEO, I look forward to seeing what their futures hold both at Selexis and as examples to women in scientific and operational roles throughout the biopharmaceutical industry.”
Myriam joined Selexis in 2012 as project leader, managing and coordinating research, experimental design, process completion, data treatment and reporting for partner projects. Subsequently, she held roles of increasing responsibility, serving as scientist in vector engineering and later as operations program manager and operations director, coordinating partner-oriented mammalian cell line generation and whole-genome sequencing programs. In the latter roles, Myriam also supported intellectual property activities. Previously, Myriam was a scientist at École Polytechnique fédérale de Lausanne (EPFL) and project leader, gene expression and analytics at ExcellGene SA. She held postdoctoral positions at Centre of Immunology Marseille-Luminy, University of Geneva-CMU and Geneva Hospital. Myriam earned her PhD in botanical sciences from the University of Liège, Belgium.
Séverine joined Selexis in 2015 as director, cell line services, leading the bioprocess and analytics departments. She ensures the continuous generation of high-performance stable cell lines, including recombinant protein characterization. Séverine also works on providing scale-down bioreactor data using ambr® 15 to facilitate the transfer to contract manufacturing organizations (CMOs). Séverine earned her PhD in protein engineering from a private company, Novimmune, where she focused on the generation of broad-spectrum chemokine inhibitors by using directed mutagenesis, phage display isolation, functional characterization and epitope mapping. She subsequently held a postdoctoral position at the University of Geneva where she designed a novel phage display platform for accelerating bispecific antibody development.
Valérie joined Selexis in 2010 as director, cell culture addressing specific secretion bottlenecks of difficult-to-express recombinant proteins. Valérie received her PhD from the University of Aix-Marseille II, where she focused on human thrombopoietin (hTPO) maturation and the role of endoplasmic reticulum (ER) chaperones in the folding/degradation machineries of this difficult-to-express glycoprotein. After completing her PhD, Valérie held a postdoctoral position at the UniversitätsSpital Zürich (Cell and Molecular Pathology Department) where she described a selective autophagy-mediated mechanism of misfolded and aggregated proteins that are retained in the ER compartment.
About Selexis SA
Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 130 drug products in clinical development and the manufacture of seven commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
FOR MORE INFORMATION